Natera Inc is a leading genetic testing company focused on transforming patient care through innovative genetic insights. Its mission is to improve health outcomes by providing comprehensive genetic information that empowers patients and healthcare providers. Natera's strategy revolves around leveraging advanced technology and data analytics to deliver non-invasive prenatal testing, oncology solutions, and organ transplantation compatibility assessments. By integrating cutting-edge science with a commitment to accessibility, Natera Inc aims to enhance the understanding of genetic conditions and support personalized medicine, ultimately driving better healthcare decisions and outcomes for patients worldwide.

NATERA INC

Natera has made significant strides in the liquid biopsy market by announcing that its Signatera test for molecular residual disease has now received coverage from the US Centers for Medicare and Medicaid Services (CMS). This coverage is particularly relevant for non-small cell lung cancer (NSCLC) surveillance, specifically in patients diagnosed...

Natera's Signatera Test Gains CMS Coverage for NSCLC Surveillance, Enhancing Medicare Support and Bolstering Liquid Biopsy Market Growth